Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis

2020

Background and aims: HCV eradication improves non-hepatic outcomes such as cardiovascular diseases, although without clearly defined mechanisms. In this study we aimed to assess whether improvement of carotid atherosclerosis may be linked to a reduction in systemic oxidative stress after viral clearance. Methods: We studied a retrospective cohort of 105 patients (age 62.4 ± 11.2 years; 62 men) with F3/F4 fibrosis, characterized by carotid ultrasonography at baseline and at sustained virologic response (SVR) follow-up. Levels of 8-iso-prostaglandin F2α (F2-isoprostanes) and other oxidative stress markers were measured on frozen sera. Association between change (denoted as Δ) in oxidative str…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virus2-isoprostanesHepacivirusmedicine.disease_causeAntiviral AgentsCarotid Intima-Media ThicknessGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineatherosclerosiFFibrosisSettore BIO/13 - Biologia ApplicataInternal medicinemedicineHumansintima-media thicknessAgedRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologybusiness.industrycirrhosisCarotid ultrasonographylipid peroxidationMiddle Agedmedicine.diseaseHepatitis CIsoprostanesatherosclerosis; cirrhosis; F; 2; -isoprostanes; intima-media thickness; lipid peroxidationOxidative StressIntima-media thickness030220 oncology & carcinogenesis030211 gastroenterology & hepatologyatherosclerosisbusinessOxidative stresscirrhosi
researchProduct

Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

2007

We evaluated the safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2a (PEG-IFN(alpha-2a)) and ribavirin in the early phase of recurrent hepatitis C after orthotopic liver transplantation (OLT). In this prospective study, 26 patients transplanted for hepatitis C virus cirrhosis with recurrent hepatitis C were treated 3.4 +/- 3.6 months after OLT and compared with an untreated historical control. PEG-IFN(alpha-2a) was initiated as monotherapy, following stepwise dose escalation up to 180 mug/week and the addition of ribavirin up to 1200 mg/day or maximally tolerated doses for 48 weeks. In the intent-to-treat analysis, 38% showed an early virological response (EVR…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene GlycolsCohort Studieschemistry.chemical_compoundPostoperative ComplicationsPegylated interferonRecurrenceInternal medicineRibavirinmedicineHumansAdverse effectAgedTransplantationbusiness.industryRibavirinInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsLiver TransplantationRegimenTreatment OutcomechemistryImmunologyRNA ViralFemalebusinessmedicine.drugTransplant International
researchProduct

Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis.

2021

INTRODUCTION: Serum biomarkers for the diagnosis of minimal hepatic encephalopathy (MHE) in patients with liver cirrhosis would be desirable. In this proof-of-concept study, we investigated the association between MHE and serum levels of neurofilament light chains (sNfL) in patients with liver cirrhosis. METHODS: sNfL were studied in patients with liver cirrhosis (with or without MHE) and controls (patients with ischemic stroke, transitory ischemic attack, and healthy individuals). MHE was diagnosed using the Psychometric Hepatic Encephalopathy Score. RESULTS: Patients with MHE showed higher sNfL than patients without MHE and controls. In multivariable analyses, higher sNfL were independent…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisNeurofilament lightGastroenterologyProof of Concept StudySeverity of Illness IndexSerum biomarkersNeurofilament ProteinsInternal medicineMedicineHumansIn patientHepatic encephalopathyAgedbusiness.industryBrief ReportGastroenterologyArea under the curveMiddle Agedmedicine.diseaseHealthy individualsHepatic EncephalopathyIschemic strokeFemalebusinesshuman activitiesBiomarkersClinical and translational gastroenterology
researchProduct

Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension

2010

Background: Oesophagogastroduodenoscopy is currently recommended for the screening of varices in cirrhosis. In addition to the assessment of varices, oesophagogastroduodenoscopy can detect conditions that, while unrelated to portal hypertension, may require treatment. Aims: We evaluated in a large cohort of cirrhotic patients the prevalence of upper digestive findings other than oesophagogastric varices, the associations between upper gastrointestinal findings, portal hypertension and features of cirrhosis, and the incidence of new lesions in the course of a surveillance program. Methods: Analysis of the records of 611 consecutive cirrhotic patients undergoing oesophagogastroduodenoscopy fo…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPepticPortal hypertensive gastropathyAdenocarcinomaEsophageal and Gastric VaricesGastroenterologyAsymptomaticHelicobacter InfectionsPolypsStomach NeoplasmsInternal medicineHypertension PortalPrevalenceHumansMedicineEndoscopy Digestive SystemStomach UlcerVascular DiseasesAgedMetaplasiaHelicobacter pyloriHepatologymedicine.diagnostic_testbusiness.industrycirrhosisIncidence (epidemiology)GastroenterologyMiddle Agedmedicine.diseaseEndoscopyDuodenal UlcerGastritisPortal hypertensionFemalemedicine.symptombusinessVaricesDigestive and Liver Disease
researchProduct

Health-related quality of life in patients with compensated and decompensated liver cirrhosis.

2019

Compensated (Child-Pugh [CP] A) and decompensated (CP B/C) liver cirrhosis significantly differs in terms of impairment of health-related quality of life (HRQoL). However, sufficient data on potentially treatable factors associated with HRQoL in both stages of the disease are still lacking. Consequently, aims of this study were to determine differences in HRQoL between patients with compensated and decompensated liver cirrhosis and to identify potentially treatable factors associated with HRQoL.218 patients with liver cirrhosis were enrolled into this study. Chronic Liver Disease Questionnaire (CLDQ) was used to assess HRQoL. Covert hepatic encephalopathy (CHE) was diagnosed according to a …

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsDisease030204 cardiovascular system & hematologyChronic liver diseaseGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicineGermanySurveys and QuestionnairesInternal MedicinemedicineHumansRoutine clinical practiceIn patient030212 general & internal medicineProspective StudiesHepatic encephalopathyAgedHealth related quality of lifebusiness.industryMiddle Agedmedicine.diseasehumanitiesHepatic EncephalopathyMultivariate AnalysisLinear ModelsQuality of LifeFemalebusinessEuropean journal of internal medicine
researchProduct

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

2020

INTRODUCTION: Despite the negative impact of covert hepatic encephalopathy on the outcome of patients with liver cirrhosis, data regarding the ability of different testing strategies to predict overt hepatic encephalopathy (OHE) development and mortality are limited. This study aimed to compare the ability of Psychometric Hepatic Encephalopathy Score (PHES), critical flicker frequency (CFF), simplified animal naming test (S-ANT1), and clinical covert hepatic encephalopathy (CCHE) score to predict OHE development and mortality. METHODS: A total of 224 patients with liver cirrhosis were tested with different testing strategies and prospectively followed up regarding clinically relevant outcom…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationRisk AssessmentSeverity of Illness IndexArticleEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicinePredictive Value of TestsInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyHepatic encephalopathyAgedReceiver operating characteristicbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyFeasibility Studies030211 gastroenterology & hepatologyFemalebusinessFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct

Impact of antithrombin III on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis

2005

AIM: To analyze the hepatic and intestinal microcirculation in an animal model of liver cirrhosis and inflammatory bowel disease (IBD) and to characterize the anti-inflammatory action of antithrombin III (ATIII) on leukocyte kinetics and liver damage. METHODS: Hepatic and intestinal microcirculation was investigated by intravital videomicroscopy. Standardized models of experimental chronic liver cirrhosis and bowel inflammation were employed. Animals were divided into four groups (n = 6/group): controls, animals with cirrhosis, animals with cirrhosis and IBD, animals with cirrhosis and IBD treated with ATIII. RESULTS: Cirrhosis facilitated leukocyte rolling and sticking in hepatic sinusoids…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSerine Proteinase InhibitorsAntithrombin IIIInflammationInflammatory bowel diseaseGastroenterologyMicrocirculationEnteritisInternal medicineMedicineAnimalsRats WistarLiver injurybusiness.industryMicrocirculationAntithrombinGastroenterologyGeneral MedicineBlood flowmedicine.diseasedigestive system diseasesEnteritisRatsIntestinesLiverBrief Reportsmedicine.symptombusinessmedicine.drug
researchProduct

Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns

2017

International guidelines suggest ultrasound surveillance for hepatocellular carcinoma (HCC) early diagnosis in liver cirrhosis (LC) patients, but 40% of nodules <2 cm escape detection. We investigated the existence of an ultrasound pattern indicating a higher risk of developing HCC in patients under surveillance. 359 patients with LC (Child-Pugh A-B8) underwent ultrasound screening (median follow-up 54 months, range 12–90 months), liver function tests, alpha-fetoprotein assay, and portal hypertension evaluation. Echo patterns were homogeneous, bright liver, coarse, coarse small nodular pattern, and coarse large nodular pattern. During follow-up 13.9% developed HCC. At multivariate analys…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaCarcinoma HepatocellularArticle Subjectlcsh:MedicineGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyDisease-Free Survival03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumansRisk factorAgedUltrasonographyGeneral Immunology and Microbiologybusiness.industryUltrasoundlcsh:RLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseUltrasound HCC Liver Cirrhosis Echo Patterns Surveillancedigestive system diseasesSurvival RateNodular PatternHomogeneous030220 oncology & carcinogenesisHepatocellular carcinomaPortal hypertension030211 gastroenterology & hepatologyFemaleRadiologybusinessResearch ArticleFollow-Up StudiesBioMed Research International
researchProduct

Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency

2015

Backgrounds and aims: Adrenal insufficiency (AI) has been reported in patients with stable cirrhosis. A lack of substrates has been suggested as a possible contributing pathogenic mechanism leading to glucocorticoid deficiency in these subjects. To better explore this hypothesis, we studied lipoproteins in cirrhotics with and without AI. Methods. A total of 81 cirrhotic patients and 30 normal volunteers were enrolled. The severity of liver disease was graded by Child-Pugh score. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein AI (Apo-AI) levels were evaluated. HDL subfractions were measured by gradient gel electrop…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHydrocortisoneCohort StudiesLiver diseasechemistry.chemical_compoundHDL cholesterolInternal medicineHDL cholesterol; adrenal insufficiency; cirrhosismedicineAdrenal insufficiencyHumansTriglyceridesAgedHydrocortisoneApolipoprotein AICirrhosiApolipoprotein A-ITriglyceridebusiness.industrycirrhosisCholesterol HDLCase-control studyGastroenterologyMiddle Agedmedicine.diseaseLipoproteins LDLEndocrinologychemistryCase-Control StudiesMultivariate AnalysisFemalelipids (amino acids peptides and proteins)Lipoproteins HDLbusinessadrenal insufficiencyGlucocorticoidmedicine.drugLipoprotein
researchProduct

Nontumorous portal vein thrombosis in liver cirrhosis: Possible role of β-blockers

2018

<b><i>Objective:</i></b> Nonselective β-blockers (NSBB) are used in liver cirrhosis (LC) to prevent variceal bleeding because they decrease portal pressure. A main risk factor for the development of portal vein thrombosis (PVT) in LC is decreased portal vein inflow velocity. The aim of our study was to examine retrospectively the incidence of PVT and its correlation with the use of β-blockers in a cohort of LC patients. <b><i>Subjects and Methods:</i></b> Data from 230 LC patients (90% Child-Pugh class A), who had been followed up for at least 5 years, were reviewed. The diagnosis of PVT was made by ultrasound. The presence of PVT was evaluate…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaPortal venous pressureCirrhosis complicationAdrenergic beta-AntagonistsNonselective β-blockerGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineEsophageal varicesRisk FactorsInternal medicineAscitesmedicineHumansRisk factorBleeding prevention therapyRisk of thrombosiAgedRetrospective StudiesAged 80 and overVenous ThrombosisUnivariate analysisOriginal Paperbusiness.industryPortal VeinIncidence (epidemiology)Medicine (all)General MedicineMiddle Agedmedicine.diseasePortal vein thrombosisLogistic ModelsItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalemedicine.symptombusiness
researchProduct